EHN/ESC call for action on CVD cost

13 March 2006

Cardiovascular disease costs European Union member states 463.0 million euros ($556.0 million) a day and it is time for an action strategy to prevent CVD across the region, a joint statement from the European Heart Network and European Society of Cardiology, made at their conference, Women's Health at Heart: Promoting Cardiovascular Health and Preventing CVD, held under the auspices of the EU's Austrian Presidency in Brussels, Belgium on March 7.

"I welcome this conference and its focus on heart health of women. The European Commission will continue to support efforts to prevent CVD, primarily through taking action on the underlying determinants of heart health - such as nutrition and physical activity, tobacco smoking and alcohol abuse," said Markos Kyprianou, Commissioner for Health and Consumer Affairs.

MEPs "must do more"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight